Part,  Chapter, Paragraph

  1    I,     2. 10.  2    |     molecular diagnostic, imaging, drug discovery and drug delivery
  2    I,     2. 10.  2    |        imaging, drug discovery and drug delivery and therapy, for
  3    I,     2. 10.  2    |        also used in biomedicine as drug carriers;~- Ceramic nanoparticles:
  4    I,     2. 10.  2    |          surface that can act as a drug vehicle;~- Liposomes: lipid-based
  5    I,     2. 10.  2    |            cosmetic industries for drug delivery;~- Emulsions: oil-water
  6    I,     2. 10.  4    |            than 30% of all adverse drug events are preventable and
  7    I,     2. 10.  4    |            each day due to adverse drug errors9. Around 10% of admissions
  8    I,     2. 10.  4    |           9% of prescriptions12.~ ~Drug counterfeiting~ ~In Europe,
  9    I,     2. 10.  4    |          predicts that counterfeit drug sales will reach US$ 75
 10    I,     2. 10.  4    |          30% cost reduction in the drug supply chain20.~ ~Current
 11   II,     5.  2.  4    |      through healthy lifestyle and drug treatment for individuals
 12   II,     5.  3.  7    |       access new innovative cancer drug treatments and the importance
 13   II,     5.  3.  7    |     authorization is obtained, the drug is available at national
 14   II,     5.  3.  7    |             regarding a new cancer drug is done quickly to facilitate,
 15   II,     5.  3.  7    |          must jointly plan for new drug introductions with a perspective
 16   II,     5.  3.  7    |       entire life cycle of any new drug, including the premium period
 17   II,     5.  3.  7    |        rapidly increasing when the drug is also used in the adjuvant
 18   II,     5.  4.  2    |                  5.4.2.8. National drug sales~ ~Some studies have
 19   II,     5.  4.  2    |     studies have utilised national drug sales to estimate prevalence
 20   II,     5.  4.  2    |         mellitus). National annual drug sales are recorded in most
 21   II,     5.  4.  8    |              1993): Utilization of drug sales data for the epidemiology
 22   II,     5.  5.  3    |             self-induced vomiting, drug abuse and excessive exercise
 23   II,     5.  5.  3    |        dieting, physical activity, drug abuse (laxatives, diuretics,
 24   II,     5.  5.  3    |            Despite improvements in drug therapy and in mental health
 25   II,     5.  5.  3    |           next highest use of this drug class (Knapp et al, 2007).
 26   II,     5.  5.  3    |            practice of focusing on drug therapy and neglecting psychosocial
 27   II,     5.  5.  3    |        does not have a therapeutic drug policy or an essential drug
 28   II,     5.  5.  3    |        drug policy or an essential drug list. One fifth of countries
 29   II,     5.  5.  3    |      dominated by hospitalization; drug costs represented only 7%
 30   II,     5.  5.  3    |         and further improvement of drug therapy;~· ensure the delivery
 31   II,     5.  5.  3    |   disorders with alcohol and other drug abuse. Results from the
 32   II,     5.  5.  3    |  Barraclough, 1997). Antipsychotic drug intake was associated with
 33   II,     5.  5.  3    |             2001): The dynamics of drug treatment in epilepsy: an
 34   II,     5.  5.  3    |       Acronyms~ ~AED~Antiepileptic Drug~CFR~Case Fatality Ratio~
 35   II,     5.  5.  3    |   inpatient care, outpatient care, drug costs and tests], non-medical
 36   II,     5.  5.  3    |            cost, and within these, drug costs dominate with €2.5
 37   II,     5.  5.  3    |         records. Pharmacoepidemiol Drug Saf 10(6):549-554.~Vanacore
 38   II,     5.  8.  3    |        hospitalisations and 31% to drug consumption (Detournay et
 39   II,     5.  9. FB    |           conjunctivitis, food and drug hypersensitivities. Allergens
 40   II,     5.  9.  3    |             to specialist visits). Drug costs make up 37% of the
 41   II,     5. 10.  2    |      Unspecified adverse effect of drug, medicament and biological
 42   II,     5. 11.  1    |            e.g. caused by a severe drug reaction) has many systemic
 43   II,     5. 11.  3    |            and wasp venom allergy, drug rashes such as the carbamazepine
 44   II,     5. 11.  4    |        diseases such as blistering drug reactions can result in
 45   II,     5. 12.  3    |      including endoscopic banding, drug treatment and transjugular
 46   II,     5. 15.  1    |          potential market size for drug development. In this case,
 47   II,     5. 15.  1    |           the cost of developing a drug will not be counterbalanced
 48   II,     5. 15.  1    |           and biomedical research, drug research and development,
 49   II,     5. 15.  6    |         call for a national orphan drug review policy. CMAJ. 2006
 50   II,     6.Acr        |      Papilloma Virus~IDU~Injecting Drug Users~LGV~Lymphogranuloma
 51   II,     6.Acr        |     Escherichia coli~XDR~Extensive Drug Resistance~YFV~Yellow Fever
 52   II,     6.  3.  2    |        line antibiotics (extensive drug resistance, XDR), poses
 53   II,     6.  3.  2    |       countries in surveillance of drug resistance is needed to
 54   II,     6.  3.  3    |       cases of HIV among injecting drug users (IDU) accounts for
 55   II,     6.  3.  3    |     cirrhosis or cancer. Injecting drug use is the dominant mode
 56   II,     6.  3.  4    |           TB and high frequency of drug resistance and where HIV
 57   II,     6.  3.  4    |        rare, and levels of HIV and drug resistance low.~ ~ ~In 2005,
 58   II,     6.  3.  4    |            homeless, prisoners and drug users.~ ~TB is more common
 59   II,     6.  3.  4    |    surveillance on risk groups and drug resistance and to better
 60   II,     6.  3.  6    |      infections do not require any drug treatment, invasive infections
 61   II,     7.  4.  6    |   schizophrenia, alcohol and other drug use, and anxiety disorders;~·
 62   II,     9            | environmental teratogen (such as a drug taken during early pregnancy).
 63   II,     9            |           selection of the type of drug is needed to balance risks
 64   II,     9            |         difficult to study, as the drug use may be illegal and there
 65   II,     9.  1.  2    | environmental teratogen (such as a drug taken during early pregnancy).
 66   II,     9.  1.  2    |           selection of the type of drug is needed to balance risks
 67   II,     9.  1.  2    |         difficult to study, as the drug use may be illegal and there
 68   II,     9.  1.  2    |       maternal infection, maternal drug exposure, occupational exposures
 69   II,     9.  1.  2    |    diseases and towards developing drug treatments for genetic diseases.
 70   II,     9.  2.  1    |  consumption, tobacco use, illegal drug use, obesity/overweight,
 71   II,     9.  2.  3    |       foreign-born and intravenous drug users. It is also thought
 72   II,     9.  2.  3    |       alcohol, tobacco and illegal drug use (WHO, 2005a).~ ~Good
 73   II,     9.  3.  1    |      change is more effective than drug treatment in reducing the
 74   II,     9.  3.  1    |        transfusion and intravenous drug, while in Eastern Europe
 75   II,     9.  3.  1    |       transmission and intravenous drug use. The public health impact
 76   II,     9.  3.  1    |         more recently, intravenous drug users (IDUs) with an HIV
 77   II,     9.  3.  1    |           been amongst intravenous drug users, while a growing proportion
 78   II,     9.  3.  1    |    Federation Atlas~IDUs~Injecting drug users~LOH~Late Onset Hypogonadism~
 79   II,     9.  3.  3    |        risk behaviours (especially drug and alcohol use), school
 80   II,     9.  4.  5    |         pressure sores and adverse drug reactions if not treated
 81   II,     9.  4.  5    |          of quality indicators for drug use and better co-ordination
 82  III,    10.  1.  1    |     resources, ability to cope and drug protective competence. The
 83  III,    10.  1.  3    |            of multilevel analyses. Drug Alcohol Depend 84(2):167-
 84  III,    10.  1.  3    |           O (1998): Competence and drug use: theoretical frameworks,
 85  III,    10.  1.  3    |        evidence and measurement. J Drug Educ 28(2):117-134.~Marcus
 86  III,    10.  1.  3    |       Suicide risk associated with drug and alcohol addiction. Cleve
 87  III,    10.  1.  3    |       Suicide risk associated with drug and alcohol dependence.
 88  III,    10.  2.  1    |      Cigarette is a very efficient drug delivery system. When tobacco
 89  III,    10.  2.  1    |        kick” caused in part by the drug’s stimulation of the adrenal
 90  III,    10.  2.  1    |           nicotine as an addictive drug has been instrumental in
 91  III,    10.  2.  1    |     Bupropion is an antidepressant drug that reduces withdrawal
 92  III,    10.  2.  1    |    Estimate of the social costs of drug abuse in Australia in 1998-
 93  III,    10.  2.  1    |   Australia in 1998-1999. National Drug Strategy Monograph Series
 94  III,    10.  2.  1    |          past, present and future. Drug and Alcohol Review, 2006;
 95  III,    10.  2.  1    |              National Institute on Drug Abuse (NIDA, USA) (2006):
 96  III,    10.  2.  1    |            in Sweden. Contemporary Drug Problems 11, 325-353.~ ~
 97  III,    10.  2.  1    |    Monitoring Centre for Drugs and Drug Addiction~ESPAD~European
 98  III,    10.  2.  1    |    Hepatitis C Virus~IDU~Injecting Drug Users~NSP~Needle and Syringe
 99  III,    10.  2.  1    |            Population with Problem Drug Use~POU~Problem Opioid Use~
100  III,    10.  2.  1    |   Information Network on Drugs and Drug Addiction~TDI~Treatment
101  III,    10.  2.  1    |  substances are also increasing.~ ~Drug use occurs overall mainly
102  III,    10.  2.  1    |           when considering regular drug use. The routes of administration
103  III,    10.  2.  1    |            an indicator of problem drug use. The frequency of use
104  III,    10.  2.  1    |  understand the characteristics of drug problems at individual and
105  III,    10.  2.  1    |         health problems related to drug use include acute problems
106  III,    10.  2.  1    |           chronic problems such as drug dependence and other mental
107  III,    10.  2.  1    |     situation of long term problem drug users should also be taken
108  III,    10.  2.  1    |      health burden associated with drug use in Europe is still difficult
109  III,    10.  2.  1    |          200 000 former or current drug injectors living with HIV
110  III,    10.  2.  1    |    Monitoring Centre for Drugs and Drug Addiction (EMCDDA) through
111  III,    10.  2.  1    |            an annual report on the drug situation in Europe and
112  III,    10.  2.  1    |          others intensive forms of drug use, including problem drug
113  III,    10.  2.  1    |        drug use, including problem drug use and addiction/dependence.~
114  III,    10.  2.  1    |    epidemiological indicators ((i) drug use among the general population; (
115  III,    10.  2.  1    |           population; (ii) problem drug use; (iii) drug related
116  III,    10.  2.  1    |            problem drug use; (iii) drug related infectious diseases; (
117  III,    10.  2.  1    |         deaths and mortality among drug users; (v) demand for drug
118  III,    10.  2.  1    |         drug users; (v) demand for drug treatment), but also other
119  III,    10.  2.  1    |             harm reduction, etc.), drug market and crime (seizures,
120  III,    10.  2.  1    |            frequently used illicit drug in Europe, but most individuals
121  III,    10.  2.  1    |            associated with current drug use across the EU are young
122  III,    10.  2.  1    |      nightclubs and bars5.~ ~Early drug use~ ~Use of illicit drugs
123  III,    10.  2.  1    |          who have already used the drug 40 or more times in their
124  III,    10.  2.  1    |            rates for other illicit drug use are much lower than
125  III,    10.  2.  1(5) |            2006 selected issues on drug use in recreational settings: htt l)~
126  III,    10.  2.  1    |        among 15-16y-old students~ ~Drug use among young adults (
127  III,    10.  2.  1    |             15-34 year old)~ ~Most drug use is taking place among
128  III,    10.  2.  1    |         young adults have used the drug and 1% have used it in the
129  III,    10.  2.  1    |           2. Overview of last year drug prevalence estimates from
130  III,    10.  2.  1    |           adults (aged 15 to 34)~ ~Drug use in the European Union
131  III,    10.  2.  1    |          surveys~ ~Most of illicit drug use recorded in general
132  III,    10.  2.  1    |          cannabis users.~ ~Problem drug use~ ~General population
133  III,    10.  2.  1    |    intensive to dependent forms of drug use, especially for substances
134  III,    10.  2.  1    |   population consisting of problem drug users (PDUs), treatment
135  III,    10.  2.  1    |              treatment demands and drug overdoses statistics also
136  III,    10.  2.  1    |          to be considered.~Problem drug use is defined by the EMCDDA
137  III,    10.  2.  1    |           the EMCDDA as ‘injecting drug use or long duration / regular
138  III,    10.  2.  1    |         methods. In total, problem drug users estimates from different
139  III,    10.  2.  1    |   estimates include only injecting drug users (IDUs) and problem
140  III,    10.  2.  1    |         opioid users and injecting drug users still remain the main
141  III,    10.  2.  1    |            remain the main problem drug use subgroups found in almost
142  III,    10.  2.  1    |         Table 10.2.1.3.2Problem Drug Use estimates: Problem opioid
143  III,    10.  2.  1    |           opioid use and injecting drug use~ ~Recent estimates on
144  III,    10.  2.  1    |           with HIV or hepatitis or drug overdose. National estimates
145  III,    10.  2.  1    |          problem.~ ~Time trends in drug use~ ~The important development
146  III,    10.  2.  1    |          the main trends regarding drug use and drug-related problems.
147  III,    10.  2.  1    |       mainly heroin, and injecting drug use during the 80s and the
148  III,    10.  2.  1    |          infectious diseases among drug users. While EU Member States
149  III,    10.  2.  1    |       drug-related problems, other drug use patterns surfaced. Cannabis
150  III,    10.  2.  1    |            only the second wave of drug use increase during the
151  III,    10.  2.  1    |           be observed that illicit drug use has increased during
152  III,    10.  2.  1    |       between countries.~ ~Problem drug use has also changed in
153  III,    10.  2.  1    |   transmission of HIV in injecting drug users (IDUs) continued in
154  III,    10.  2.  1    |         number of IDUs and problem drug users it has been estimated
155  III,    10.  2.  1    |      living with HIV who have been drug injectors in their lives.~ ~
156  III,    10.  2.  1    |         prevalence among injecting drug usersstudies with national
157  III,    10.  2.  1    |           2004-2005, all injecting drug users~ ~In recent years,
158  III,    10.  2.  1    |         infections among injecting drug users is very widespread
159  III,    10.  2.  1    |         number of IDUs and problem drug users lead to an estimate
160  III,    10.  2.  1    |            in the EU who have been drug injectors in their lives.~ ~
161  III,    10.  2.  1    |         prevalence among injecting drug users, 2004-2005, all injecting
162  III,    10.  2.  1    |           2004-2005, all injecting drug users~ ~Among the other
163  III,    10.  2.  1    |          levels.~ ~Mortality among drug users12~ ~A multi-country
164  III,    10.  2.  1    |         found that mortality among drug users is 6-20 times higher
165  III,    10.  2.  1    |  attributed to opioids use, mainly drug overdoses, AIDS accidents
166  III,    10.  2.  1(12)|    Information on the mortality of drug users comes from cohort
167  III,    10.  2.  1(12)|       generalizable to all problem drug users in the country.~
168  III,    10.  2.  1    |         and Norway~ ~More than one drug is mentioned in 60-90% of
169  III,    10.  2.  1    |         heroin, have been the main drug for which treatment is seeked.
170  III,    10.  2.  1    |          were recorded as the main drug in about 40% of all cases.
171  III,    10.  2.  1    |           cannabis, cocaine is the drug most commonly reported as
172  III,    10.  2.  1    |          doubled. European data on drug users entering treatment
173  III,    10.  2.  1    |           increasing, this form of drug use is rarely the primary
174  III,    10.  2.  1    |       primary reason for attending drug treatment in the EU.~ ~Figure
175  III,    10.  2.  1    |   treatment, subdivided by primary drug used~ ~
176  III,    10.  2.  1    |         psychoactive substances18.~Drug related problems have been
177  III,    10.  2.  1    |     European action plan to combat drug problems was adopted in
178  III,    10.  2.  1    |         1990. The current European drug strategy runs for the period
179  III,    10.  2.  1    |      countries now have a national drug strategy and/or a national
180  III,    10.  2.  1    |         strategy and/or a national drug action plan. These encompass
181  III,    10.  2.  1    |       action plan. These encompass drug supply reduction (law enforcement)
182  III,    10.  2.  1    |    reduction (law enforcement) and drug demand reduction (prevention,
183  III,    10.  2.  1    |        better understanding of the drug problem and of the impact
184  III,    10.  2.  1    |          main priority in national drug strategies and action plans.
185  III,    10.  2.  1    |         reducing the acceptance of drug use. However, so far only
186  III,    10.  2.  1    |           development of municipal drug plans has been reported
187  III,    10.  2.  1    |           opiate use and injecting drug use in the eighties and
188  III,    10.  2.  1    |           hepatitis B and C) among drug users have triggered the
189  III,    10.  2.  1    |          000 opioid users received drug substitution treatment in
190  III,    10.  2.  1    |             helping former problem drug users to access a job and
191  III,    10.  2.  1    |        part of the response to the drug problem in Europe. However,
192  III,    10.  2.  1    |            health-risks related to drug injecting. The exchange
193  III,    10.  2.  1    |     countries also have supervised drug consumption facilities.
194  III,    10.  2.  1    |       After a dramatic increase in drug use and drug-related problems
195  III,    10.  2.  1    |     historical standards levels of drug use are high and, although
196  III,    10.  2.  1    |         observable and patterns of drug use still differ, the polarised
197  III,    10.  2.  1    |        common European patterns of drug use.~ ~Historically, the
198  III,    10.  2.  1    |            the changing picture of drug use has prompted an awareness
199  III,    10.  2.  1    |        concern for those providing drug services. This ’widening
200  III,    10.  2.  1    |           heterogonous patterns of drug consumption resulting into
201  III,    10.  2.  1    |       pattern among many groups of drug users and problem drug users
202  III,    10.  2.  1    |          of drug users and problem drug users in Europe. Poly–drug
203  III,    10.  2.  1    |         drug users in Europe. Poly–drug use issues are not restricted
204  III,    10.  2.  1    |  marketplace.~ ~It is not just new drug consumption patterns and
205  III,    10.  2.  1    |          will remain the focus for drug responses in the future.
206  III,    10.  2.  1    |        current or past use of this drug will remain major consumers
207  III,    10.  2.  1    |       ageing population of problem drug users presents multiple
208  III,    10.  2.  1    |        involved in helping problem drug users or regarding the accessibility
209  III,    10.  2.  1    |             The description of the drug situation presented above
210  III,    10.  2.  1    |        considerable investments in drug research and monitoring
211  III,    10.  2.  1    |        over the last twenty years. Drug policies and their evaluation
212  III,    10.  2.  1    |   mentioned, risk behaviours among drug users, long-term treatment
213  III,    10.  2.  1    |            Mortality among problem drug users in Europe: a project
214  III,    10.  2.  1    |    Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Heroin
215  III,    10.  2.  1    |    Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual
216  III,    10.  2.  1    |      EMCDDA (2000): Opioid use and drug injection http ~ ~EMCDDA (
217  III,    10.  2.  1    |             2006): Select issue on Drug Use In Recreational Settings.
218  III,    10.  2.  1    |     Implementing School Surveys on Drug Abuse . Available at:~htt ~ ~
219  III,    10.  2.  1    |                 Farrell, M. (1995) Drug prevention: a review of
220  III,    10.  2.  4    |       drugs and the development of drug targets~· the role of genomic
221  III,    10.  3.  3    |      infections do not require any drug treatment, invasive infections
222  III,    10.  4.  3    |        sludge. Increased levels of drug residues have been observed
223  III,    10.  5.  2    |    pathologies such as alcohol and drug dependence being more prevalent
224  III,    10.  6.  2    |          mental health problems or drug abuse. The project is located
225  III,    10.  6.  2    |           is to reduce alcohol and drug abuse and improve health
226   IV,    11.  1.  3    |           introducing prescription drug budgets (e.g. in Germany).~ ~
227   IV,    11.  1.  5    |    traditional responsibilities of drug preparation and verification.
228   IV,    11.  1.  5    |            developed to facilitate drug treatment decision-making
229   IV,    11.  1.  5    |    patients have avoidable adverse drug events and, consequently,
230   IV,    11.  2.  2    |    health promotion, cancer, AIDS, drug dependence, health monitoring,
231   IV,    11.  3.  2    |            of the original branded drug (as in Belgium, fixed at
232   IV,    11.  3.  2    |         the therapeutic value of a drug and clinical gains. While
233   IV,    11.  3.  2    |           equivalent for a branded drug. In some countries physicians
234   IV,    11.  3.  2    |   countries to global prescription drug market by value (2006)~ ~
235   IV,    11.  3.  2    |            world with prescription drug sales of $181.8bn in 2006.
236   IV,    11.  6.  2    |        Level of income~Age~Type of drug~ ~Pregnancy services:~-
237   IV,    11.  6.  2    |            UK~ ~Cheapest effective drug:~- Czech Republic~ ~Related
238   IV,    11.  6.  5    |     European survey of independent drug information centres,." Annals
239   IV,    11.  6.  5    |            severity of intravenous drug errors." British Medical
240   IV,    12.Acr        |       Tobacco Control~FDA~Food and Drug Administration~GNP~Gross
241   IV,    12.  1        |       risks associated with them. ~Drug prevention~The aim was to
242   IV,    12.  1        |           was to help in combating drug dependence, in particular
243   IV,    12.  2        |     Bupropion is an antidepressant drug that reduces withdrawal
244   IV,    12.  4        |    Monitoring Centre for Drugs and Drug Addiction (Lisbon, Portugal) -
245   IV,    12.  4        |         level concerning drugs and drug addiction and their consequences.~ ~
246   IV,    12.  8        |            example the US Food and Drug Administration (FDA) and
247   IV,    12. 10        |   Koch-Institute (see www.rki.de); Drug Affinity among Young People (
248   IV,    12. 10        |    Koch-Institute (see www. e) and Drug Affinity among Young People (
249   IV,    12. 10        |         important tasks of Federal Drug Coordinator (Bundesdrogenbeauftragte,
250   IV,    12. 10        |            together). Alcohol (and drug addiction in general) prevention
251   IV,    12. 10        |          Security. Legislation and drug policy are as well part
252   IV,    12. 10        |    Institutions exists for illegal drug dependants (Suchtkrankenhilfe).
253   IV,    12. 10        |     self-help organizations (e. g. drug counselling centres).~ ~
254   IV,    12. 10        |         centres).~ ~ Prevention of drug and substance abuse is one
255   IV,    12. 10        |         important tasks of Federal Drug Coordinator (Bundesdrogenbeauftragte,
256   IV,    12. 10        | Intervention Of First Time Noticed Drug Users: FreD” – aimed to
257   IV,    12. 10        |        aimed to discourage further drug abuse among young people (
258   IV,    12. 10        |       ex-user and people receiving drug substitution” – networking
259   IV,    12. 10        |       Addiction Report” of Federal Drug Coordinator (annually release,
260   IV,    12. 10        |             European data-bank for drug related programs and interventions).~
261   IV,    12. 10        |            Action Plan to optimize drug safety (Aktionsplan 2008/
262   IV,    12. 10        |            of medical devices.~The Drug Commission of the German
263   IV,    12. 10        |      information and guidelines on drug safety.~Critical incident
264   IV,    12. 10        |          action plans to deal with~drug misuse within their areas
265   IV,    12. 10        |   co-ordinated response to illicit drug use~at local/regional level,
266   IV,    12. 10        |    Treatment~Services with Serious Drug Problems~was published in
267   IV,    12. 10        |          meet changing patterns of drug use~particularly regarding
268   IV,    12. 10        |          are indirectly related to drug use. ~To remedy these limitations,
269   IV,    12. 10        |      jointly asked the Alcohol and~Drug Research Unit of the Health~
270   IV,    12. 10        |            in Ireland - Evaluating Drug Treatment Effectiveness)
271   IV,    12. 10        |         follow~up to the 2002/2003 Drug Prevalence Study~was carried
272   IV,    12. 10        |           in January 2008~examined drug use in Ireland & Northern~
273   IV,    12. 10        |         Products~ State Program on drug Control and Drug Addiction
274   IV,    12. 10        |        Program on drug Control and Drug Addiction Restriction 2005-
275   IV,    12. 10        |      national level~Action Plan on Drug Abuse Control for the Period
276   IV,    12. 10        |          Period 2006-2009~National Drug Control Strategy in the
277   IV,    13.Acr        |    health promotion, cancer, AIDS, drug dependence, health monitoring,
278   IV,    13.  5        |     tobacco related mortality, and drug resistant tuberculosis.
279   IV,    13.  8        |            NGOs. Most notably, for drug prevention, preventive sexual
280  Key,   Ap5.  0.  0    |          drought~droughts~drowning~drug~drug-induced~drug-resistant~